☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Atopic
The US FDA Extends Review Period of Olumiant's sNDA to Treat Moderate to Severe Atopic Dermatitis
April 7, 2021
Load more...
Back to Home